← SEC 公告列表 | AUTL SEC 公告 | Autolus Therapeutics Plc（AUTL）

重大事件 即時報告 8-K 2026-06-29

Autolus Therapeutics 2026年度股東大會六項決議全數通過 股東支持強勁

於 SEC 網站開啟原文

AI 繁中摘要

📄 **8-K 申報：Autolus Therapeutics plc 2026 年度股東大會投票結果** Autolus Therapeutics plc 於 2026 年 6 月 29 日舉行年度股東大會（AGM），會上就六項決議進行投票，全部獲得通過。以下是各項決議的投票結果摘要： ✅ **決議 1：接收及採納截至 2025 年 12 月 31 日止財政年度的賬目及相關報告** 贊成：165,846,326 票 | 反對：2,895,344 票 | 棄權：75,901 票 議案獲得壓倒性支持。 ✅ **決議 2：批准董事薪酬報告（不包括薪酬政策）** 贊成：156,192,216 票 | 反對：12,502,946 票 | 棄權：122,409 票 雖然反對票數相對較高，但仍以超過 92% 贊成率通過。 ✅ **決議 3：委任 Ernst & Young LLP (US) 為核數師，任期至 2027 年 AGM，並授權董事釐定核數師薪酬** 贊成：165,871,368 票 | 反對：2,872,225 票 | 棄權：73,978 票 核數師委任獲得廣泛認可。 ✅ **決議 4：重選 Mr. M Bonney 為董事** 贊成：165,491,394 票 | 反對：3,312,126 票 | 棄權：14,051 票 ✅ **決議 5：重選 Dr. E Leiderman 為董事** 贊成：165,741,204 票 | 反對：3,063,838 票 | 棄權：12,529 票 ✅ **決議 6：重選 Mr. RW Azelby 為董事** 贊成：162,133,091 票 | 反對：6,671,776 票 | 棄權：12,704 票 三位董事候選人均以高票順利連任，反映股東對現有管理團隊的信心。 🔍 **對投資者的影響**： 所有決議均獲通過，顯示股東對公司財務報告、薪酬安排、審計團隊及董事會組成表示認同。公司管治穩定性獲得確認，無重大股東異議事項，有利於維持市場信心。
展開英文正文 
autl-202606290001730463FALSE00017304632026-06-292026-06-290001730463sic:Z88802026-06-292026-06-290001730463us-gaap:CommonClassAMember2026-06-292026-06-29

UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT 
Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): June 29, 2026

Autolus Therapeutics plc
(Exact name of registrant as specified in its Charter)

England and Wales
001-38547Not applicable

(State or other jurisdiction of incorporation or organization)
(Commission File Number)(I.R.S. Employer Identification No.)

The Mediaworks

191 Wood Lane

LondonW12 7FP
United Kingdom
(Address of principal executive offices)(Zip Code)

(44) 203829 6230

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share
AUTLThe Nasdaq Global Select Market
Ordinary shares, nominal value $0.000042 per share**The Nasdaq Stock Market LLC*

*
Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 29, 2026, Autolus Therapeutics plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the six resolutions set forth below, each of which were voted on and duly passed on a poll at the AGM. Each resolution is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 5, 2026 (the “Proxy Statement”). Set forth below are the results, including the number of votes cast for, against and abstentions, with respect to each of the resolutions submitted for a vote of the shareholders at the AGM. An abstention is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a particular resolution.
Ordinary Resolutions
Resolution 1: To receive and adopt the Company’s accounts for the financial year ended 31 December 2025 and the associated reports of the Directors and auditors (the “2025 Annual Report and Accounts”). The votes were cast as follows:

ForAgainstAbstain
165,846,3262,895,34475,901

Resolution 2: To approve the Directors’ remuneration report (excluding the Directors’ remuneration policy), as set out on pages 38 to 67 of the 2025 Annual Report and Accounts. The votes were cast as follows:

ForAgainstAbstain
156,192,21612,502,946122,409

Resolution 3: To appoint Ernst & Young LLP (US) as auditors of the Company to hold office from the conclusion of the 2026 AGM until the conclusion of the 2027 AGM and to authorize the Directors to determine the auditors’ remuneration. The votes were cast as follows:

ForAgainstAbstain
165,871,3682,872,22573,978

Resolution 4: To re-elect Mr. M Bonney as a Director. The votes were cast as follows:

ForAgainstAbstain
165,491,3943,312,12614,051

Resolution 5: To re-elect Dr. E Leiderman as a Director. The votes were cast as follows:

ForAgainstAbstain
165,741,2043,063,83812,529

Resolution 6: To re-elect Mr. RW Azelby as a Director. The votes were cast as follows:

ForAgainstAbstain
162,133,0916,671,77612,704

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AUTOLUS THERAPEUTICS PLC
Dated: June 29, 2025By:/s/Christian Itin, Ph.D.
Name: Christian Itin, Ph.D.
Title: Chief Executive Officer